Glimric-MV2 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 2 mg, Metformin 500 mg, and Voglibose 0.2 mg, targeting multiple pathophysiological defects associated with diabetes. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in a reduction of postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active components, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with metformin and voglibose. Glimric-MV2 is indicated as adjunctive therapy to diet and exercise for patients inadequately controlled on monotherapy or dual therapy with these agents. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Use under medical supervision is recommended to optimize treatment outcomes and minimize adverse effects.